CA2921778A1 - Inhibition of a lncrna for treatment of melanoma - Google Patents
Inhibition of a lncrna for treatment of melanoma Download PDFInfo
- Publication number
- CA2921778A1 CA2921778A1 CA2921778A CA2921778A CA2921778A1 CA 2921778 A1 CA2921778 A1 CA 2921778A1 CA 2921778 A CA2921778 A CA 2921778A CA 2921778 A CA2921778 A CA 2921778A CA 2921778 A1 CA2921778 A1 CA 2921778A1
- Authority
- CA
- Canada
- Prior art keywords
- linc01212
- melanoma
- inhibitor
- expression
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 143
- 238000011282 treatment Methods 0.000 title claims abstract description 23
- 230000005764 inhibitory process Effects 0.000 title abstract description 24
- 108091046869 Telomeric non-coding RNA Proteins 0.000 title abstract description 9
- 210000004027 cell Anatomy 0.000 claims abstract description 79
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 108091007717 SAMMSON Proteins 0.000 claims description 134
- 230000014509 gene expression Effects 0.000 claims description 84
- 239000003112 inhibitor Substances 0.000 claims description 45
- 108020004459 Small interfering RNA Proteins 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 39
- 230000001965 increasing effect Effects 0.000 claims description 25
- 230000006907 apoptotic process Effects 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 13
- 102100039788 GTPase NRas Human genes 0.000 claims description 11
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 11
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 11
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 11
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 11
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims description 9
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 7
- 238000010459 TALEN Methods 0.000 claims description 5
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 5
- 210000004881 tumor cell Anatomy 0.000 claims description 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 229940102297 B-raf kinase inhibitor Drugs 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 229940123690 Raf kinase inhibitor Drugs 0.000 claims 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 1
- 239000002774 b raf kinase inhibitor Substances 0.000 claims 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 claims 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 claims 1
- 210000002752 melanocyte Anatomy 0.000 abstract description 22
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000006882 induction of apoptosis Effects 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 description 86
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 32
- 230000035772 mutation Effects 0.000 description 30
- 239000002773 nucleotide Substances 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 29
- 239000000047 product Substances 0.000 description 27
- 102000013760 Microphthalmia-Associated Transcription Factor Human genes 0.000 description 23
- 108010050345 Microphthalmia-Associated Transcription Factor Proteins 0.000 description 23
- 230000037361 pathway Effects 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 230000000692 anti-sense effect Effects 0.000 description 16
- 238000003197 gene knockdown Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 14
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 102000043136 MAP kinase family Human genes 0.000 description 11
- 108091054455 MAP kinase family Proteins 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 230000002779 inactivation Effects 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 230000002018 overexpression Effects 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 239000003184 complementary RNA Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 238000010195 expression analysis Methods 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 7
- 108020005544 Antisense RNA Proteins 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000009368 gene silencing by RNA Effects 0.000 description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 230000004654 survival pathway Effects 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 101710203526 Integrase Proteins 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 102000013814 Wnt Human genes 0.000 description 5
- 108050003627 Wnt Proteins 0.000 description 5
- 239000000074 antisense oligonucleotide Substances 0.000 description 5
- 238000012230 antisense oligonucleotides Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 108090000994 Catalytic RNA Proteins 0.000 description 4
- 102000053642 Catalytic RNA Human genes 0.000 description 4
- 241000252212 Danio rerio Species 0.000 description 4
- 229940124647 MEK inhibitor Drugs 0.000 description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000010199 gene set enrichment analysis Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 108091092562 ribozyme Proteins 0.000 description 4
- 201000000849 skin cancer Diseases 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102100034283 Annexin A5 Human genes 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 102000017274 MDM4 Human genes 0.000 description 3
- 108050005300 MDM4 Proteins 0.000 description 3
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 102100027881 Tumor protein 63 Human genes 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000002074 deregulated effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 208000021039 metastatic melanoma Diseases 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 description 2
- 102000047934 Caspase-3/7 Human genes 0.000 description 2
- 108700037887 Caspase-3/7 Proteins 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 2
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 208000007256 Nevus Diseases 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 description 2
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 108020004417 Untranslated RNA Proteins 0.000 description 2
- 102000039634 Untranslated RNA Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229960001924 melphalan Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- -1 ribonucleoside phosphoramidites Chemical class 0.000 description 2
- 102200055464 rs113488022 Human genes 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 1
- 108050006685 Apoptosis regulator BAX Proteins 0.000 description 1
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 description 1
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 229940125431 BRAF inhibitor Drugs 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021573 Bcl-2-binding component 3, isoforms 3/4 Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000010446 CRISPR interference Methods 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 238000001353 Chip-sequencing Methods 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000003350 DNA copy number gain Effects 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 239000012824 ERK inhibitor Substances 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100031150 Growth arrest and DNA damage-inducible protein GADD45 alpha Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000773083 Homo sapiens 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000971203 Homo sapiens Bcl-2-binding component 3, isoforms 1/2 Proteins 0.000 description 1
- 101000971209 Homo sapiens Bcl-2-binding component 3, isoforms 3/4 Proteins 0.000 description 1
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 1
- 101001127470 Homo sapiens p53 apoptosis effector related to PMP-22 Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 108020005198 Long Noncoding RNA Proteins 0.000 description 1
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- WJNVUXXUQLHUEU-UHFFFAOYSA-N OP(O)(O)=S.OP(O)(O)=S.O.O.O Chemical compound OP(O)(O)=S.OP(O)(O)=S.O.O.O WJNVUXXUQLHUEU-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108091008611 Protein Kinase B Proteins 0.000 description 1
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000004156 Wnt signaling pathway Effects 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000002814 antineoplastic antimetabolite Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000003021 clonogenic effect Effects 0.000 description 1
- 230000006552 constitutive activation Effects 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 150000008266 deoxy sugars Chemical class 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 238000010457 gene scissor Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000000370 laser capture micro-dissection Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000004777 loss-of-function mutation Effects 0.000 description 1
- 229940123729 mTOR kinase inhibitor Drugs 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 102100030898 p53 apoptosis effector related to PMP-22 Human genes 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037436 splice-site mutation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 229960003862 vemurafenib Drugs 0.000 description 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13181001 | 2013-08-20 | ||
| EP13181001.2 | 2013-08-20 | ||
| PCT/EP2014/067781 WO2015024986A1 (en) | 2013-08-20 | 2014-08-20 | INHIBITION OF A lncRNA FOR TREATMENT OF MELANOMA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2921778A1 true CA2921778A1 (en) | 2015-02-26 |
Family
ID=48986048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2921778A Pending CA2921778A1 (en) | 2013-08-20 | 2014-08-20 | Inhibition of a lncrna for treatment of melanoma |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9821004B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3036326B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105705640B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014310564B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2921778A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3036326T3 (cg-RX-API-DMAC7.html) |
| NO (1) | NO3036326T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015024986A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| NO3036326T3 (cg-RX-API-DMAC7.html) | 2013-08-20 | 2018-03-03 | ||
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| JP6772062B2 (ja) | 2013-12-02 | 2020-10-21 | フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． | 癌の免疫療法 |
| US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
| US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
| EP3177718B1 (en) | 2014-07-30 | 2022-03-16 | President and Fellows of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10767182B2 (en) | 2014-11-14 | 2020-09-08 | Vib Vzw | Direct and selective inhibition of MDM4 for treatment of cancer |
| US10415095B2 (en) | 2015-04-10 | 2019-09-17 | University Of Florida Research Foundation, Incorporated | LncRNA serves as a biomarker and therapeutic target |
| US11021707B2 (en) | 2015-10-19 | 2021-06-01 | Phio Pharmaceuticals Corp. | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
| SG11201803173VA (en) | 2015-10-23 | 2018-05-30 | Harvard College | Nucleobase editors and uses thereof |
| KR20170076480A (ko) | 2015-12-24 | 2017-07-04 | 삼성전자주식회사 | Pint 유전자의 발현 저해제 또는 pint의 활성 저해제를 포함하는 조성물 및 그의 용도 |
| US10549363B2 (en) | 2016-06-27 | 2020-02-04 | Mechanical & Electrical Concepts, Inc. | Attachable and extendable saw and methods for using same |
| JP7231935B2 (ja) | 2016-08-03 | 2023-03-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | アデノシン核酸塩基編集因子およびそれらの使用 |
| CA3033327A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
| US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| AU2018352592C1 (en) | 2017-10-16 | 2025-09-25 | Beam Therapeutics, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| WO2019165212A1 (en) * | 2018-02-22 | 2019-08-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | TARGETING CANCER-ASSOCIATED LONG NON-CODING RNAs |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| GB2601617B (en) | 2019-03-19 | 2024-02-21 | Broad Inst Inc | Methods and compositions for editing nucleotide sequences |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| EP3976055A1 (en) * | 2019-05-29 | 2022-04-06 | Universiteit Gent | Combinations of therapeutic agents for treating uveal melanoma |
| KR102238594B1 (ko) * | 2019-06-07 | 2021-04-08 | 한양대학교 산학협력단 | Heres 발현 억제제를 포함하는 편평상피세포암 예방 또는 치료용 약학적 조성물 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN110898213A (zh) * | 2019-11-27 | 2020-03-24 | 西安交通大学 | LncRNA SAMMSON与BRAF激酶联合抑制在延缓黑色素瘤适应性耐药的应用 |
| CA3161513A1 (en) * | 2020-01-28 | 2021-08-05 | Irwin DAVIDSON | Antisense oligonucleotide targeting linc00518 for treating melanoma |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| CN112553208B (zh) * | 2020-12-31 | 2023-09-26 | 重庆市畜牧科学院 | 一个长链非编码rna新基因及其在制备检测或诊断早期黑变病试剂中的应用 |
| CN112760377B (zh) * | 2021-01-18 | 2023-11-03 | 南通大学附属医院 | lncRNA 068在诊断或治疗恶性黑色素瘤方面的应用 |
| WO2023086552A2 (en) * | 2021-11-12 | 2023-05-19 | The Regents Of The University Of California | Lncrna transcripts in melanomagenesis |
| EP4299742A1 (en) | 2022-06-30 | 2024-01-03 | Université de Strasbourg | Combination therapy for melanoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| EP1929043A4 (en) * | 2005-08-24 | 2009-10-28 | Genizon Biosciences Inc | GENETIC CARD OF HUMAN GENES ASSOCIATED WITH CROHN'S DISEASE |
| CN101633923B (zh) * | 2009-07-10 | 2011-04-13 | 四川大学 | 人黑色素瘤细胞相关的长非编码rna及其用途 |
| WO2012018881A2 (en) * | 2010-08-03 | 2012-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for the regulation of rna |
| US9410206B2 (en) * | 2011-11-30 | 2016-08-09 | John Wayne Cancer Institute | Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer |
| NO3036326T3 (cg-RX-API-DMAC7.html) | 2013-08-20 | 2018-03-03 |
-
2014
- 2014-08-20 NO NO14757881A patent/NO3036326T3/no unknown
- 2014-08-20 US US14/913,629 patent/US9821004B2/en not_active Ceased
- 2014-08-20 US US16/689,648 patent/USRE48801E1/en not_active Expired - Fee Related
- 2014-08-20 CN CN201480057416.5A patent/CN105705640B/zh not_active Expired - Fee Related
- 2014-08-20 CA CA2921778A patent/CA2921778A1/en active Pending
- 2014-08-20 EP EP14757881.9A patent/EP3036326B1/en active Active
- 2014-08-20 DK DK14757881.9T patent/DK3036326T3/en active
- 2014-08-20 AU AU2014310564A patent/AU2014310564B2/en not_active Ceased
- 2014-08-20 WO PCT/EP2014/067781 patent/WO2015024986A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| USRE48801E1 (en) | 2021-11-02 |
| DK3036326T3 (en) | 2018-01-08 |
| US20160271163A1 (en) | 2016-09-22 |
| CN105705640A (zh) | 2016-06-22 |
| NO3036326T3 (cg-RX-API-DMAC7.html) | 2018-03-03 |
| EP3036326B1 (en) | 2017-10-04 |
| US9821004B2 (en) | 2017-11-21 |
| CN105705640B (zh) | 2019-02-15 |
| AU2014310564B2 (en) | 2020-04-09 |
| WO2015024986A1 (en) | 2015-02-26 |
| AU2014310564A1 (en) | 2016-03-10 |
| EP3036326A1 (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014310564B2 (en) | Inhibition of a lncRNA for treatment of melanoma | |
| CA2937058C (en) | Inhibition of neat1 for treatment of solid tumors | |
| Conkrite et al. | miR-17∼ 92 cooperates with RB pathway mutations to promote retinoblastoma | |
| CN101835902B (zh) | 编码ncrna的超保守区域 | |
| CN102239260B (zh) | 通过抑制针对载脂蛋白‑a1的天然反义转录物治疗载脂蛋白‑a1相关疾病 | |
| Errico et al. | The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR‐221&222‐c‐FOS pathway | |
| Yoon et al. | Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest | |
| JP2010535782A (ja) | Ｄｎｍｔ３ａ及びｄｎｍｔ３ｂを標的にすることによるメチル化を元に戻す方法 | |
| JP7406278B2 (ja) | 腫瘍マーカー及び治療ターゲットとしての長鎖ノンコーディングｒｎａ ｌｅｔｎ | |
| He et al. | Downregulation of miR‐221 inhibits cell migration and invasion through targeting Methyl‐CpG binding domain protein 2 in human oral squamous cell carcinoma cells | |
| Siena et al. | Upregulation of the novel lncRNA U731166 is associated with migration, invasion and vemurafenib resistance in melanoma | |
| Fenderico et al. | MicroRNA-mediated control of prostate cancer metastasis: implications for the identification of novel biomarkers and therapeutic targets | |
| US11246868B2 (en) | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment | |
| Karami Fath et al. | The functional role of circular RNAs in the pathogenesis of retinoblastoma: a new potential biomarker and therapeutic target? | |
| EP3746555B1 (en) | Inhibition of a lncrna for treatment of neuroblastoma | |
| Thomas | Characterisation of the long noncoding RNA GHSROS in prostate and breast cancer | |
| Wei et al. | Regulation of Abnormal Expression of hsa_circRNA_0127523 on Proliferation, Migration and Invasion and miR-515-5p Expression in Oral Squamous Cell Carcinoma. | |
| Felicetti et al. | MicroRNAs in melanoma | |
| Chen | MicroRNA-193b functions as a tumor suppressor in malignant melanoma | |
| Romano | miR-126 and miR-126* Expression in Pulmonary Carcinomas: Future important markers of carcinogenesis | |
| Sokolova | MicroRNA involvement in colon cancer progression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190401 |
|
| EEER | Examination request |
Effective date: 20190401 |
|
| EEER | Examination request |
Effective date: 20190401 |
|
| EEER | Examination request |
Effective date: 20190401 |
|
| EEER | Examination request |
Effective date: 20190401 |
|
| EEER | Examination request |
Effective date: 20190401 |
|
| EEER | Examination request |
Effective date: 20190401 |
|
| EEER | Examination request |
Effective date: 20190401 |